Cytomegalovirus (CMV) prophylaxis in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
Antiviral agent against CMV. It inhibits the CMV DNA terminase complex (pUL51, pUL56, and pUL89), which is required for viral DNA processing, thereby interfering with virion maturation.
480 mg PO/IV once daily. Initiate between day 0 and day 28 posttransplantation (before or after engraftment) and continue through day 100.
Approval was based on a phase 3 clinical trial (n=565). In this study, significantly fewer patients developed clinically significant CMV infection in the letermovir group (38%, n=122/325) compared to the placebo group (61%, n=103/170). Additionally, fewer patients discontinued treatment or had missing data through week 24 post-HSCT (P<0.0001).
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.